NYSE and Nasdaq Delisting Criteria, Explained

Price, market-cap, and compliance thresholds.

When an exchange concludes that a listed company no longer meets its continued-listing standards, the process that follows — deficiency notice, cure period, appeal, and ultimately removal from trading — is tightly scripted. Understanding nasdaq delisting criteria, and how NYSE standards compare, matters to anyone tracking distressed equities, tracking corporate default events dataset signals, or simply trying to model the path from non-compliance to forced stock delisting. The rules are detailed, the thresholds are specific, and they change — so any serious workflow requires monitoring the actual exchange rulebooks rather than relying on a summary.

The main continued-listing standards by category

Both NYSE and Nasdaq maintain several parallel tests a company must satisfy on an ongoing basis. Failing any single standard triggers a deficiency. The principal categories are:

• Minimum bid price. The most frequently tripped standard. A company's common stock must maintain a closing bid price of at least $1.00 per share. The deficiency is triggered only after the bid falls below $1.00 for 30 consecutive trading days — a single bad day is not enough.
• Market value of listed securities / stockholders' equity. Nasdaq's tiers each carry distinct minimum market-value thresholds. The Global Select Market, Global Market, and Capital Market tiers apply different numerical floors; issuers on lower tiers face lower absolute minimums. NYSE similarly tests market capitalization and stockholders' equity, often in combination — a company may fall short on one metric but remain compliant if another is satisfied.
• Public float. A minimum market value of publicly held shares is required. The specific threshold varies by Nasdaq tier and security type.
• Round-lot holders. Exchanges require a minimum number of shareholders holding at least one round lot (typically 100 shares). This keeps a baseline of investor distribution in place.
• Corporate governance. Board composition, audit-committee independence, annual-meeting requirements, and related rules form an independent compliance category. Deficiencies here are procedural rather than financial.
• Timely filing. Failure to file annual or quarterly reports with the SEC on schedule triggers a separate deficiency independent of financial condition.

The deficiency notice and cure window

Once a deficiency is identified, the exchange issues a formal deficiency notice. The company typically has time to respond with a compliance plan before trading is suspended. For the bid-price rule specifically, the cure period is commonly 180 calendar days. After that initial window, a second 180-day extension is available under Nasdaq's rules if the company meets the initial listing standards for the relevant market tier (excluding the bid-price requirement itself) and commits to remediate — giving a total potential cure window of up to 360 days from the original notification.

NYSE procedures differ in framing: the exchange issues a notice and typically expects a remediation plan within 45 days, after which it monitors progress over a set period. The specific timelines and available extensions vary by deficiency type on both exchanges, and the exchanges retain discretion to accelerate removal if they determine the company's situation is hopeless or if additional deficiencies stack up during the cure period.

Regaining compliance

For the bid-price deficiency — the most common route to delisting — the standard path to regaining compliance is straightforward: the stock must close at or above $1.00 for at least 10 consecutive business days. The exchange then issues a compliance notification and the matter is closed.

In practice, a stock that has traded below $1.00 for months rarely recovers organically. The dominant mechanism is a reverse stock splits, which mechanically multiplies the share price by the inverse of the split ratio. A 1-for-10 reverse split, for instance, takes a $0.40 stock to $4.00 immediately. The exchange accepts this as a legitimate compliance method, though it treats the 10-consecutive-day clock as running from the effective date of the split. Companies that execute a reverse split primarily to satisfy the bid-price test, only to fall back below $1.00, may find the exchange unwilling to grant a second full cure period.

For other deficiency types — market cap, stockholders' equity, round-lot holders — there is no single mechanical fix. Equity raises, asset sales, or restructurings may restore compliance, but the exchange evaluates each case and reserves the right to delist if a credible remediation plan is absent.

The appeal and hearing process

A company facing a delisting determination can request a hearing before an exchange panel. On Nasdaq, the request stays the delisting while the hearing is pending; hearings typically occur within 45 days of the request, and the panel issues a decision thereafter. Companies can present their case for remaining listed, offer compliance plans, and in some instances receive conditional exceptions — for example, being granted additional time to complete a financing or reverse split on a specific schedule.

The Nasdaq Listing Council and NYSE's equivalent bodies handle appeals of hearing-panel decisions. The full process can extend a company's listing by several months beyond the original cure window, which is meaningful for shareholders who would otherwise face the liquidity disruption of an OTC transfer.

NYSE vs. Nasdaq: framing differences

NYSE and Nasdaq share the same broad categories but differ in structure and emphasis. Nasdaq organizes its rules by market tier — Global Select, Global Market, Capital Market — with each tier carrying its own numerical thresholds. NYSE applies a unified framework with some tier-differentiated rules for its American and main-board listings.

NYSE historically places relatively greater emphasis on market capitalization and revenue tests, while Nasdaq's deficiency process is more explicitly codified around bid price and equity-value minimums. Both exchanges have adopted similar bid-price rules and 180-day cure frameworks under Regulation NMS-era harmonization, but practitioners should consult the current rulebooks — both exchanges amend their listing standards periodically, and the numbers in a summary like this lag any recent changes.

Standards at a glance

Standard	Common trigger	Typical cure window	Common remedy
Minimum bid price ($1.00)	30 consecutive trading days below $1.00	180 days (+ 180-day extension on Nasdaq)	Reverse split; organic recovery to ≥ $1.00 for 10 consecutive days
Market value / stockholders' equity	Sustained decline below tier-specific minimum	Varies; plan typically required within 45 days	Equity raise, asset sale, restructuring
Public float	Float falls below tier minimum	Varies by exchange	Secondary offering; insider distribution
Round-lot holders	Shareholder count below minimum	Varies	Often linked to a share issuance or split
Corporate governance	Board composition or committee failure	Defined plan period; often several months	Director appointments; committee reconstitution
Timely filing	Late 10-K or 10-Q	Plan required promptly; extension possible	Filing the delinquent report

Where Alphanume fits

Deficiency notices and delisting determinations are disclosable events — companies file 8-Ks when they receive exchange notifications, and those filings surface in the same pipeline as other compliance-related corporate actions. Alphanume's corporate default events dataset tracks these and related triggers across the listed universe, giving researchers a structured event feed rather than a manual EDGAR search. For anyone modeling distressed equity paths or building systematic screens around exchange-compliance status, a normalized feed of deficiency dates, cure deadlines, and hearing outcomes is considerably more useful than raw filings.